Artelo Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	2016 - 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Aug '21 Aug 31, 2021	2016 - 2020
Net Income	-9.83	-9.29	-10.08	-12.11	-7.44	Upgrade
Loss (Gain) From Sale of Investments	-0.28	-0.64	-0.21	-0.02	0	Upgrade
Stock-Based Compensation	0.82	1.02	2.46	2.8	1.53	Upgrade
Other Operating Activities	0.03	0.04	0.04	0.03	0.01	Upgrade
Change in Accounts Payable	0.48	0.27	0.02	1.5	-0	Upgrade
Change in Other Net Operating Assets	0.43	0.39	-0.24	-0.21	-0.24	Upgrade
Operating Cash Flow	-8.35	-8.21	-8.01	-8	-6.14	Upgrade
Investment in Securities	7.77	3.51	2.96	-30.1	-3.44	Upgrade
Investing Cash Flow	7.77	3.51	2.96	-30.1	-3.44	Upgrade
Short-Term Debt Issued	-	-	-	-	0	Upgrade
Total Debt Issued	-	-	-	-	0	Upgrade
Short-Term Debt Repaid	-	-	-	-	-0.01	Upgrade
Total Debt Repaid	-	-	-	-0	-0.01	Upgrade
Net Debt Issued (Repaid)	-	-	-	-0	-0.01	Upgrade
Issuance of Common Stock	0.11	0.57	-	54.79	14.12	Upgrade
Financing Cash Flow	0.11	0.57	-	54.78	14.11	Upgrade
Foreign Exchange Rate Adjustments	-0.01	0.06	-0.22	-0.08	-0.05	Upgrade
Net Cash Flow	-0.48	-4.07	-5.27	16.6	4.49	Upgrade
Free Cash Flow	-8.35	-8.21	-8.01	-8	-6.14	Upgrade
Free Cash Flow Per Share	-2.59	-2.77	-2.83	-3.59	-4.93	Upgrade
Levered Free Cash Flow	-4.7	-4.64	-4.31	-	-3.18	Upgrade
Unlevered Free Cash Flow	-4.7	-4.64	-4.3	-	-3.18	Upgrade
Change in Net Working Capital	-0.8	-0.55	0.33	-	0.06	Upgrade

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q